Where Enanta Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) within the last quarter:
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
Jefferies Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $95
Jefferies analyst Akash Tewari initiates coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a Buy rating and announces Price Target of $95.
Enanta To Discontinue Internal Development Of NASH Candidates
After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic…
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
SVB Leerink Initiates Coverage On Enanta Pharmaceuticals with Market Perform Rating, Announces Price Target of $55
SVB Leerink analyst Roanna Ruiz initiates coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform rating and announces Price Target of $55.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 1)